Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP-14 versus R-CHOP-21 for newly diagnosed diffuse large B-cell lymphoma
ISRCTN16017947Phase 3Completed
- Sponsor
- University College London
- Start
- Mar 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by University College London. Primary endpoint: overall survival. Started Mar 2005; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN16017947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16017947.